You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

38 Results
Regimen
Intent: Palliative, Curative
Funding:
New Drug Funding Program
    Aldesleukin (interleukin-2) - In-Transit Metastases from Melanoma
May 2019
Regimen
Regimen
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Feb 2022
Regimen
Intent: Neoadjuvant, Adjuvant
Jun 2020
Regimen
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Feb 2022
Regimen
Regimen
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Feb 2022
Regimen
Intent: Neoadjuvant, Adjuvant, Palliative
May 2019
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Promyelocytic (APL)
Intent: Palliative, Curative
Funding:
Exceptional Access Program
    tretinoin (ATRA)
May 2019
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Promyelocytic (APL)
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    tretinoin (ATRA)
May 2019
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Promyelocytic (APL)
Intent: Curative
Funding:
New Drug Funding Program
    Arsenic Trioxide - First Line Consolidation of Acute Promyelocytic Leukemia (APL)
New Drug Funding Program
    Arsenic Trioxide - Relapsed_Refractory Consolidation of Acute Promyelocytic Leukemia (APL)
Exceptional Access Program
    tretinoin (ATRA)
Jul 2021
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Promyelocytic (APL)
Intent: Curative
Funding:
New Drug Funding Program
    Arsenic Trioxide - First Line Induction of Acute Promyelocytic Leukemia (APL)
New Drug Funding Program
    Arsenic Trioxide - Relapsed_Refractory Induction of Acute Promyelocytic Leukemia (APL)
Exceptional Access Program
    tretinoin (ATRA)
May 2019

Pages